The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, H. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMPHOTERICIN B
Medline Plus Health Information
*Leishmaniasis
The Journal of Immunology, 2005, 174: 4916-4923.
Copyright © 2005 by The American Association of Immunologists

Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis1

Henry W. Murray2

Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021

In visceral leishmaniasis, chemotherapy probably seldom eradicates all parasites in tissue macrophages; nevertheless, most T cell-intact patients show long-lasting clinical cure after treatment despite residual intracellular infection. To characterize prevention of posttreatment relapse, amphotericin B was used to kill ~90–95% of Leishmania donovani in livers of mice deficient in mechanisms of acquired antileishmanial resistance. Recrudescence subsequently developed 1) in animals deficient in both CD4 and CD8 T cells as well as CD40L-mediated T cell costimulation, but not in a) CD4 or CD8 cells alone, b) NK cell lytic activity, or c) ICAM-1-recruited monocytes; and 2) in mice deficient in IFN-{gamma}, but not in the IFN-{gamma}-inducing cytokines, a) IL-12, b) IL-12 and IL-23, or c) IL-18. Posttreatment recrudescence also did not develop in animals deficient in macrophage phagocyte NADPH oxidase (phox) or inducible NO synthase (iNOS) alone or, surprisingly, in those deficient in both phox and iNOS. Therefore, regulation of the intracellular replication of residual Leishmania donovani that escape chemotherapy evolves to a host mechanism distinguishable from initial acquired resistance at the T cell, cytokine, and macrophage levels. Posttreatment, either CD8 or CD4 cells can direct the response, IL-12 is not required, and iNOS and phox, the activated macrophage’s primary IFN-{gamma}-inducible leishmanicidal pathways, both become dispensable.




This article has been cited by other articles:


Home page
J. Immunol.Home page
A. Banerjee, M. De, and N. Ali
Complete Cure of Experimental Visceral Leishmaniasis with Amphotericin B in Stearylamine-Bearing Cationic Liposomes Involves Down-Regulation of IL-10 and Favorable T Cell Responses
J. Immunol., July 15, 2008; 181(2): 1386 - 1398.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
S. Bhowmick, R. Ravindran, and N. Ali
gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani
Infect. Immun., March 1, 2008; 76(3): 1003 - 1015.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Saha, S. Mondal, R. Ravindran, S. Bhowmick, D. Modak, S. Mallick, M. Rahman, S. Kar, R. Goswami, S. K. Guha, et al.
IL-10- and TGF-beta-Mediated Susceptibility in Kala-azar and Post-kala-azar Dermal Leishmaniasis: The Significance of Amphotericin B in the Control of Leishmania donovani Infection in India
J. Immunol., October 15, 2007; 179(8): 5592 - 5603.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
F. J. S. Rocha, U. Schleicher, J. Mattner, G. Alber, and C. Bogdan
Cytokines, Signaling Pathways, and Effector Molecules Required for the Control of Leishmania (Viannia) braziliensis in Mice
Infect. Immun., August 1, 2007; 75(8): 3823 - 3832.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
H. W. Murray, C. W. Tsai, J. Liu, and X. Ma
Responses to Leishmania donovani in Mice Deficient in Interleukin-12 (IL-12), IL-12/IL-23, or IL-18
Infect. Immun., July 1, 2006; 74(7): 4370 - 4374.
[Abstract] [Full Text] [PDF]


Home page
Am J Trop Med HygHome page
H. W. MURRAY, Z. XIANG, and X. MA
RESPONSES TO LEISHMANIA DONOVANI IN MICE DEFICIENT IN BOTH PHAGOCYTE OXIDASE AND INDUCIBLE NITRIC OXIDE SYNTHASE
Am J Trop Med Hyg, June 1, 2006; 74(6): 1013 - 1015.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
R. Polley, S. Stager, S. Prickett, A. Maroof, S. Zubairi, D. F. Smith, and P. M. Kaye
Adoptive Immunotherapy against Experimental Visceral Leishmaniasis with CD8+ T Cells Requires the Presence of Cognate Antigen
Infect. Immun., January 1, 2006; 74(1): 773 - 776.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.